Despite the interwoven nature of platelet activation and the coagulation system in thrombosis few studies relate both analysis of protein and cellular parts of coagulation in the same population. In the present study, we use matched ex vivo samples to determine the influences of standard anti-platelet therapies on platelet function and use advanced rheological analyses to assess clot formation. Healthy volunteers were recruited following fully informed consent then treated for 7 days with single antiplatelet therapy of aspirin (75 mg) or prasugrel (10 mg) or with dual anti-platelet therapy (DAPT) using aspirin (75 mg) plus prasugrel (10 mg) or aspirin (75mg) plus ticagrelor (90mg). Blood samples were taken at day 0 before treatment and at day 7 following treatment. We found that aspirin plus prasugrel or aspirin plus ticagrelor inhibited platelet responses to multiple agonists and reduced P-selectin expression.
Introduction
Development of the platelet-rich fibrin clot at sites of atherosclerotic plaque rupture is central to atherothrombotic disease [1] . Platelets are critical to the processes of atherothrombosis, driving thrombus formation through a cascade of complex intracellular signalling pathways and powerful positive feedback loops [2, 3] . Platelets also have a central role in cell-based regulation of the coagulation system [4] [5] [6] .
Because of the fundamental involvement of platelets in atherothrombosis, antiplatelet drugs that target amplifying secondary platelet agonists are the standard of care for the prevention of thrombotic events in patients with cardiovascular disease [7, 8] .
Aspirin irreversibly blocks the cyclooxygenase enzyme (COX) to inhibit thromboxane A2 (TXA2) production [9] whilst P2Y12 receptor antagonists such as clopidogrel and prasugrel block the effects of pro-aggregatory ADP [10] . Together these agents constitute dual antiplatelet therapy (DAPT). Despite this approach adverse thrombotic events still occur and high on-treatment platelet reactivity to ADP [11] and aspirin resistance [12] are associated with adverse clinical outcome. This has led to questioning of the current 'one size fits all approach' to DAPT and the development of the concept of tailored antithrombotic therapies. However, to date attempts to use platelet testing to personalise therapy have repeatedly failed to provide any improvement in clinical outcome in randomised clinical trials [13] [14] [15] .
Coagulation pathway changes also play central roles in clot propagation, a process that is affected by many factors both genetic and environmental [16] . Configuration of the fibrin network is a vital determinant of clot stability and susceptibility to fibrinolysis [15, 17] with clot permeability being the rate limiting factor for the activity of plasmin, the fibrin network degradation enzyme. Clots composed of compact thin fibres are associated with thrombotic events [18, 19] and clot structure appears unfavourably altered in coronary artery disease and other conditions associated with thrombosis [20] [21] [22] [23] and is also associated with adverse events following percutaneous coronary intervention. It has therefore, been suggested that there is a definitive diagnostic potential in characterising clot structure and modulation of clot architecture as a possible treatment for thrombosis [24] . However, many techniques that assess the mechanics and quality of clot architecture rely on processed samples using altered blood in remote laboratories, limiting their clinical use.
Viscoelastic properties have been shown to be the most sensitive measures of fibrin polymerisation and blood clot structure [25] and recent advances in our understanding of the viscoelastic changes taking place in coagulation have resulted in the development of new methods for the analysis of clot characteristics. These properties can be quantified using small amplitude oscillatory shear rheometry to measure the gel point (GP), a multi-faceted biomarker that defines the transition between viscoelastic fluid and viscoelastic solid states during gelation. The technique uses unadulterated whole blood and is measured immediately at the bedside during realtime clot formation, providing a rapid assessment of coagulation that can be more readily performed than current methods. In coagulating blood the GP marks the establishment of the incipient clot and provides three important characteristics of the clot, all calculated from one measurement: time taken to reach GP or gel time (TGP); clot elasticity/strength (G'GP) and the fractal dimension (df) of the incipient clot [26] .
Fractal dimension is a common technique used in biology to characterize nonlinear growth in branching network structures [27] . Importantly the measurement of df at the GP provides a quantitative assessment of clot structure where in studies using viscoelastic and imaging data it has been shown to act as the template for mature clot development [26] [27] . Reduced df is associated with more permeable, less branched and mechanically weaker clots and a raised df corresponds to a tightly packed, highly branched clot that is less permeable and stronger. Several studies have highlighted the potential of df as a biomarker in determining the effects of disease and therapeutic intervention on clot quality [26] [28] [29] [30] [31] . However, we are yet to establish the effects of individual anti-platelet therapies on clot structure and whether these are quantifiable by our novel GP technique.
Here, we therefore apply the GP technique together with standard measures of platelet reactivity in blood samples taken from healthy volunteers treated with standard antiplatelet therapies, to investigate the complex interplay of platelets in the formation of clot structure and further validate the role of GP as a possible clinical biomarker. Such an approach may well provide a globally representative marker of haemostasis and thrombosis that could permit a more personalised approach to antiplatelet therapy.
Materials and Methods

Study participants
16 healthy, male volunteers (aged 18-40 years) participated in an initial single antiplatelet therapy study. Health status was determined though medical history and physical examination, including blood pressure, pulse rate, blood chemistry and urinalysis. Volunteers with normal clinical profiles were included in the study.
Subsequently, a further 20 healthy volunteers were recruited in an identical manner for a follow-up dual anti-platelet therapy study. Both studies were approved by St Thomas's Hospital Research Ethics Committee (Ref. 07/Q0702/24) and all volunteers gave written consent before entering the study.
Study protocol
All healthy volunteers abstained from aspirin, non-steroidal anti-inflammatory drugs 
Blood collection
In all cases blood was obtained from an antecubital vein via a 19-gauge butterfly needle and all experiments were completed within 2 hours of blood collection.
Laboratory markers
Blood was taken for full blood count (FBC) analysis, including platelet count and haemoglobin into 4ml EDTA vacutainers and into 4.5ml citrate vacutainers (BD Biosciences, UK) for routine coagulation studies, including prothrombin time (PT), without anti-coagulant were transferred directly and immediately (< 60 seconds) after sampling to a double-gap concentric cylinder geometry of a TA instruments Discovery HR-2 controlled stress rheometer (New Castle, DE, USA). All work was conducted at 37(±0.1) °C and all measurements were made on aliquots of the same sample by use of similar measuring geometries with identical measuring surfaces and surface preparation procedures. The viscoelastic properties of incipient clots were determined by detecting the Gel Point (GP) of samples of whole unadulterated blood using small amplitude oscillatory shear rheometry [32] . From which the values of TGP and df were measured. The GP technique used in this study has been previously validated for use with blood elsewhere in several other studies [26, [29] [30] [31] [32] . The value of df measured at the GP can be equated to the mass of the clot. In previous studies we have shown there is an exponential relationship between df and clot mass [33] . In the present study we recreated this relationship and used it to calculate the relative mass (RM) for each of the df values. In this approach the mass of a random fractal aggregate (RFA) varies as a function of fractal dimension, via the following scaling law ( )~, where are the characteristic length scales of the RFA (we assume the fibrin structure to be fractal over the range (100nm -60 m) commensurate with light scattering experiments conducted by Ferri et al. [34] .
Scanning Electron Microscopy
For scanning electron microscopy (SEM) samples at each time point were allowed to clot at 37°C for a minimum of 15 mins. Samples were then washed three times with 2 cocadylate buffer pH 7.2 for the removal of excess salt and fixed for a minimum of 4 h in 2% glutaraldehyde solution. The clots were then rinsed with cocadylate buffer and dehydrated in a series of ethanol concentrations from 30 to 100%. The clots were then critical point dried with hexamethyldisilazane for 45 min and placed in a fume hood for 24 hrs. Finally, the clots were mounted to 0.5" SEM stubs (Agar Scientific, UK) and sputter coated with gold palladium. All samples were investigated with a Hitachi S4800 scanning electron microscope (Hitachi, High-Technologies Corporation, Tokoyo, Japan) [35] . All images were acquired with a constant resolution of 5.0kV
(accelerating voltage) and a semi-in-lens achieving ultra-high resolution. A combination of upper and lower signal detectors were used to collect the electron signals.
Statistics and Data Analysis
Clot fractal dimension (df), relative mass (RM) and haematological and haemostatic data were analysed by Wilcoxon signed rank tests. Pearson correlation coefficients were calculated for df and TGP versus haematological and haemostatic parameters.
Flow cytometry data was analysed using FlowJo v8.7 (Treestar, Ashland, USA) where the "single platelet" population was gated based on forward scatter and CD61-APC immunoreactivity (FL-4 mean fluorescence intensity). Unless otherwise stated, platelet response data in LTA, lumi-aggregometry and flow cytometry was analysed by paired t-test, using Prism v6.0e (Graphpad software, USA). Statistical significance was determined as described above and data sets considered different if p<0.05.
Results
Effects of aspirin (75 mg) therapy on platelet reactivity and fractal analysis of incipient clots
In individuals taking aspirin, standard LTA responses to AA (1 mM) and collagen (0.4 µg/ml) were strongly inhibited. Responses to ADP (5 µM) were also significantly reduced whilst those to ADP (20 µM), collagen (4 µg/ml), U46619 (10 µM) and TRAP-6 (25 µM) were unaffected ( Figure 1A) . Similarly, aspirin therapy did not affect dense granule secretion induced by collagen (4 µg/ml) as measured by ATP release ( Figure   1B ), or TRAP-6 (25 µM) induced PAC-1 binding ( Figure 1C ) and p-selectin expression ( Figure 1D ). Haematological parameters, selected haemostatic parameters and gel time were not altered (Supplementary, 
Effects of prasugrel (10 mg) monotherapy on platelet reactivity and fractal analysis of incipient clots
Following prasugrel therapy aggregatory responses to AA (1 mM), collagen (0.4 and 4 µg/ml), ADP (5 and 20 µM), as well as U46619 (10 µM) were all significantly reduced. TRAP-6 (25 µM)-induced aggregation however, was unaffected ( Figure 2A ). ATP release induced by collagen (4 µg/ml) was significantly decreased (Figure 2B) , as was TRAP-6 (25 µM) induced PAC-1 ( Figure 2C ) and p-selectin expression ( Figure 2D ).
Haematological parameters, and selected haemostatic parameters and gel time were not altered (Supplementary, 
Characterisation of dual anti-platelet therapy with aspirin (75mg) plus prasugrel (10 mg) on platelet reactivity and fractal analysis of incipient clots
Platelet aggregation induced by AA (1mM), collagen (0.4 µg/ml) and ADP (5 µM and 20 µM) in LTA were abolished in individuals taking prasugrel plus aspirin whilst responses to collagen (4 µg/ml), U46619 (10 µM) and TRAP-6 (25 µM) were also all significantly inhibited ( Figure 3A ). TRAP-6 (25 µM) induced p-selectin expression was also decreased ( Figure 3B ). There was a significant reduction in the df value were powerfully inhibited and those to collagen (4 µg/ml), U46619 (10 µM) and TRAP-6 (25 µM) were significantly reduced ( Figure 4A ). These reductions were associated with a reduction in p-selectin expression (p<0.05; Figure 4B) Scanning electron microscopy demonstrated that dual anti-platelet therapy resulted in formation of clots with reduced fibrin density and increased fibrin strand diameter ( Figure 5 ). This reduction in clot density was consistent with the df measurements and projections of random fractal aggregates for the aspirin plus prasugrel and aspirin plus ticagrelor groups showing a reduction in the density of connectedness compared to that projected from blood collected under control conditions ( Figure 6 ).
Correlation analysis between fractal analysis and other parameters
The relationships between pre and post treatment values of df and the haemostatic, haematological and platelet parameters are shown in Table 1 
Discussion
Here using an advanced viscoelastic technique we have identified that platelets are potential regulators of clot structure under clinically relevant conditions. This and previous studies show that our technique could be applied to investigate the functional relationship between coagulation pathways, platelets, eventual clot quality and outcome. This is relevant as increased platelet reactivity represents an important and potentially modifiable risk factor for thrombosis 40 ; if reliably identified then it could be modified by individualised anti-platelet therapy regimes. A possible limitation of standard kinetic markers is their focus on individual components of platelet reactivity, coagulation or fibrinolysis alone which fails to distinguish abnormal clot architecture.
Our study is the first to apply the measurement of df to quantify differences in structural organisation and mechanical properties of blood clots secondary to individual and Table 1) .
In control conditions we observed platelet reactivity responses within the normal ranges reported for healthy volunteers [11, 36, 37] . Following treatment with aspirin or prasugrel we noted powerful inhibition of platelet responses to AA or ADP respectively, in keeping with consensus statement indicators of effective therapy [11, 37] . Aspirin monotherapy also inhibited platelet aggregations induced by low concentrations of ADP and collagen. ATP release, activation of GP IIb/IIIa receptors and p-selectin expression were not significantly affected. In accordance with these limited effects on platelet function, aspirin produced no significant change in clot structure as detected by df (1.71±0.01 to 1.69±0.01, p=0.41). The change in mean relative mass was also non-significant (-8±19% change, p=0.47). Prasugrel monotherapy substantially blunted platelet aggregation responses to all agonists tested apart from TRAP-6 and caused significant reductions in ATP release, p-selectin expression and GP IIb/IIIa receptor activation. Platelet inhibition was associated with both a significant reduction in df (1.72±0.02 to 1.67±0.01, p =0.03) and a considerable change in the mean relative mass of incipient clots (-40±11% change, p=0.03) indicative of a substantial change in structure.
Following our monotherapy studies, which indicated a strong association between platelet activity and clot architecture we then sought to characterise the influences of dual anti-platelet therapy. Administration of aspirin plus prasugrel or aspirin plus ticagrelor resulted in significant levels of platelet inhibition to all agonists, abolishing responses to weaker agonists tested. P-selectin expression was also significantly reduced in both groups. Again, significant platelet inhibition was coupled with a reduction in df: aspirin plus prasugrel (1.73±0.02 to 1.68±0.02, p=0.03) and aspirin plus ticagrelor (1.72±0.03 to 1.62±0.02, p=0.04). There were also significant reductions in mean relative mass both for aspirin plus prasugrel (-35±16% change, p=0.04) and for aspirin plus ticagrelor (-45±14% change, p=0.04).
Overall the anti-platelet therapies had little effect on haematological and haemostatic parameters (Supplemental Tables 2,3 ,4,5 & 7) but the changes in Df did correlate with changes in the platelet reactivity tests (see Table 1 ). Whilst as noted above, df correlates with fibrinogen concentration it is important to note that fibrinogen concentrations did not change between the pre-and post-measurements for any of the anti-platelet drugs tested (aspirin, prasugrel, aspirin plus prasugrel, and aspirin plus ticagrelor). This indicates that the magnitude of df is not solely dependent on the amount of fibrinogen present, but also how the processes through which fibrinogen forms a fibrin network dependent upon platelet reactivity.
Overall our results clearly demonstrate that stronger inhibition of platelet function is Figure 5) . These SEM images, in keeping with our previous studies highlight that incipient clot structure quantified by df acts as a template to predict the structure of the mature clot. Notably, the fibrin strands are much thicker in the post-as opposed to the pre-treatment images (df 1.67 versus df 1.63) and the number of small round particles, which represent platelets, is much reduced. This is in keeping with the association of thick fibrin strands with more porous clots and reduced platelet-fibrin interactions which we could expect following DAPT with aspirin plus ticagrelor in our healthy volunteer subject.
Results from our studies using standard single and dual anti-platelet therapy demonstrate that it is activation of P2Y12 receptors that is the key driver of platelet interactions in clot formation, in keeping with the contribution of ADP but not TXA2 receptors in the initiation of intravascular coagulation [38] . We did not observe a significant microstructural change in volunteers taking aspirin 75mg, in keeping with a minimal reduction in platelet reactivity. This contrasts with a recent study, where treatment with 300mg aspirin in patients with ischaemic stroke produced a significant reduction in df. [28] Aspirin primarily acts to inhibit platelet cyclo-oxygenase-1 however, at higher doses it exerts other effects such as acetylation of fibrinogen, prothrombin and other coagulation factors [39] [40] . Therefore, we could anticipate to detect this direct role in clot modulation with higher doses of aspirin (300mg) but perhaps not at lower doses (75mg) and this difference was readily detectable by our global haemorheological marker of clot structure. It is also notable that addition of aspirin to prasugrel produced no further reduction in markers of clot density despite additional inhibition of platelet thromboxane A2 pathways. As we have suggested previously this may indicate that in the presence of strong P2Y12 receptor blockade aspirin produces little or no additional therapeutic benefit [41, 42] .
Our results are readily understandable as platelets are central to several key coagulation processes. Activated platelets expose phosphatidylserine to support the function of the prothrombinase complex greatly enhancing coagulation [43] , interact with many coagulation factors [44, 45] and associate with tissue factor [46] . Platelets are instrumental in providing a surface for large scale thrombin production [47] and are involved in fibrin formation and organisation with activated GPIIb/IIIa receptors regulating clot retraction [48] . Previous studies have shown that platelets are important in fibrin fibre growth where the fibres originate from the platelet aggregates in clots formed in platelet-rich plasma [49] . This is an important consideration in understanding df as it is derived from a viscoelastic measurement of the incipient clot formation, where the fibrin network provides the dominant viscoelastic response [26] . Dense regions of fibres would inevitably influence the viscoelastic properties and consequently the value of df. Therefore, platelets as the promotors of fibrin fibre growth would contribute to an increase in elasticity and thus a corresponding increase in the df. Consequently, in the presence of platelet inhibition and hence a reduction in the number, or absence, of platelet aggregates a lower value of df would be expected.
In the present study comparison of responses in the absence and presence of different levels of platelet inhibition identifies a significant relationship between platelet function and the complex, highly disordered structure of incipient clots in whole unadulterated blood from healthy volunteers, echoing a previous report that altered clot structures are associated with aspirin treatment failure [50] . As well as providing further mechanistic insight into the links between platelet reactivity and clot formation, our data indicates that the therapeutic benefits of anti-platelet therapies are dependent upon their abilities to reduce thrombus density. Analysis of our SEM micrographs further confirms that these anti-thrombotic effects are partly attributable to the formation of thicker fibrin fibres, increased volume of pore spaces and an increased permeability of the clot's fibrinolytic components. This deeper understanding of the role of platelets in thrombus formation could be useful in individual patients to determine the functional relationship between platelet reactivity, eventual clot quality and clinical outcome. Tables   Table 1. Pearson correlation coefficients and high density regions respectively). A RFA realisation containing many red areas denotes a more compact, densely connected structure than a RFA with predominately green areas.
